MeiraGTx Corp (MGTX) - Market Capitalization to Book Value Ratio

MeiraGTx PLC (MGTX) - corporate logo

MeiraGTx Holdings plc (MGTX) operates within a secure geopolitical environment, conducting global research without trade restrictions. The business relies on exclusive patents in genetic medicine, creating monopoly conditions and a steady cash flow. This price action reflects market dynamics fixed at 4.11. Meanwhile, the company strictly adheres to bioethical principles and minimizes environmental impact during waste disposal.

MeiraGTx Corp (MGTX) Capitalization to Book Value Ratio: for the period 07/04/2022 - 11/01/2026

Analytical breakdowns and data insights for company MeiraGTx Holdings (MGTX)

- share price and consensus valuation forecast:
Stock Quotes MeiraGTx Holdings plc|MGTX - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization MeiraGTx PLC|MGTX - Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share MeiraGTx|MGTX - Accounting Capitalization|Market Capitalization to Book Value Ratio meiragtx.com|MGTX - Company Total Assets
- debt and solvency information:
Debt to Equity MeiraGTx Holdings plc|MGTX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital MeiraGTx PLC|MGTX - Company Cumulative Debt|Debts to Book Capitalization MeiraGTx PLC|MGTX - Long-Term Debt Volume|Company Short-Term Debt MeiraGTx|Quick Ratio meiragtx.com
- earnings and market multiples details:
MGTX - Net Profit
Comprehensive company analysis:MeiraGTx Holdings plc - MGTX
Manufactured product of MeiraGTx Holdings

This chart reflects the gap between the market price of MeiraGTx Holdings plc (MGTX) and the value of its net assets, measuring the premium the market is willing to pay for future successes in gene therapy. By analyzing the price-to-book ratio, an investor can see the extent of the valuation premium relative to tangible resources, which, coupled with high capital burn and clinical failures, critically increases the risk of a total loss of investment.

Competitors of MeiraGTx Holdings plc (MGTX)

TEM (Tempus Labs) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio QGEN|IONS (Ionis) - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio RGEN (Repligen Corp)|Market Value to Book Value Ratio Avidity (RNA)|CRISPR - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio WGS (GeneDx Holdings Corp.)|Market Capitalization to Book Value Ratio ultragenyx.com RARE|BEAM - Market Value to Book Value Ratio|Sarepta Therapeutics (SRPT) - Market Cap to Net Assets Ratio|TWST: Market Capitalization to Book Value Ratio|Market-to-Book Ratio 10x (TXG)|NTLA (Intellia Therapeutics) - Market Capitalization to Book Value Ratio|stoketherapeutics.com (STOK) - Market Capitalization to Book Value|Market Value to Book Value Ratio BioLife Solutions (BLFS)|WVE (Wave Life Sciences Ltd) - Market Value to Book Value|Market Capitalization to Book Value Ratio MAZE (Maze Tx)|Market Capitalization to Book Value Ratio Sionna Corp SION|Prime Medicine, Inc. - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio tayshagtx.com (TSHA)|QURE (uniQure) - Market Cap to Net Assets Ratio|RGNX: Market Cap to Book Value Multiple|Market Cap to Net Assets Ratio SLDB|Capitalization to Book Value Ratio OCGN (Ocugen Pharma)|Market Cap to Net Assets Ratio PACB (Pacific Biosciences)|BNTC (benitec.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio DSGN (Design Therapeutics, Inc.)|Market Value to Book Value RCKT|FDMT - Market Value to Book Value Ratio|Market-to-Book Ratio Lexeo Therapeutics|korrobio.com (KRRO) - Market Value to Book Value Ratio|EDIT (editasmedicine.com) - Market Value to Book Value Ratio|SLN (Silence Therapeutics plc) - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio PRQR (ProQR Therapeutics NV)|Market Capitalization to Book Value Ratio CDXS|Market Capitalization to Book Value Sangamo BioSciences|Market Value to Book Value Ratio Nautilus Bio NAUT|MGX: Capitalization to Book Value Ratio|Precision BioSciences - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Generation Bio Co. (GBIO)|Boundless Bio, Inc (BOLD) - Market Value to Book Value Ratio|XCUR - Market Capitalization to Book Value|Market Cap to Net Assets Ratio IMNN|PHIO: Market Value to Book Value|Market Value to Book Value Ratio Mustang Bio, Inc. (MBIO)|RNAZ: Market Capitalization to Net Assets|Market Value to Book Value Ratio Bionano Genomics BNGO|Applied DNA Corp - Market Value to Book Value Ratio|bluebird bio, Inc. - Market Capitalization to Book Value Ratio|ImmunoPrecise Antibodies (IPA) - Market Cap to Net Assets Ratio|Omega Therapeutics, Inc. (OMGA) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Singular Genomics Systems, Inc.|RGLS (Regulus Therapeutics Inc) - Market Capitalization to Book Value Ratio|SYRS - Market Value to Equity Ratio|Market Cap to Net Assets Ratio TBIO (Telesis Bio, Inc.)|Market Cap to Book Value Multiple TCON|Unity Biotechnology, Inc. - Market Cap to Net Assets Ratio